CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
TriLink BioTechnologies has signed a licensing agreement with QuantiBact to offer twisted intercalating nucleic acid (TINA) modified oligonucleotides.
TINA molecules are intercalators placed at the 5’ end of primers to stabilize duplex formation. Their properties improve the sensitivity and specificity of endpoint and real-time PCR. TINA oligos may find applications wherever an enhanced Tm is required, such as triplex formation or gene silencing.
TINA-modified oligonucleotides are now available from TriLink. Visit trilink biotech.com/TINA for up-to-date information.
TriLink BioTechnologies, 800-863-6801